GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia

References

• Offringa R. Tumour immunology exploitation of the weapon of immune destruction for cancer therapy: taking aim before firing. Curr Opin Immunol 2005; 17: 159–62
   PubMedGoogle Scholar
• Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001; 250: 462–75
   PubMed Web of Science ®Google Scholar
• Liu SH, Zhang M, Zhang WG. Strategies of antigen-specific T-cell-based immunotherapy for cancer. Cancer Biother Radiopharm 2005; 20: 491–501
   PubMedGoogle Scholar
• Brentjens R, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Med 2003; 9: 279–86
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson Byrd D, Riddel S, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. PNAS 2002; 99: 16168–73
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T-lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372–7
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346–57
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–4
   PubMed Web of Science ®Google Scholar
• Melief CJ, Toes RE, Medema JP, et al. Strategies for immunotherapy of cancer. Adv Immunol 2000; 75: 235–82
   PubMed Web of Science ®Google Scholar
• Schnurr M, Scholz C, Rothenfusser S, et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and T cells. Cancer Res 2002; 62: 2347–52
   PubMed Web of Science ®Google Scholar
• Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor specific cytotoxic lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 2001; 91: 749–56
   PubMed Web of Science ®Google Scholar
• Montagna D, Schiavo R, Gibelli N, et al. Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. Int J Cancer 2004; 110: 76–86
   PubMedGoogle Scholar
• Croce MV, Colussi AG, Segal-Eiras A. Assessment of methods for primary tissue culture of human breast epithelia. J Exp Clin Cancer Res 1998; 17: 19–26
   PubMed Web of Science ®Google Scholar
• Freshney RI. Induction of differentiation in neoplastic cells. Anticancer Res 1985; 5: 111–16
   PubMed Web of Science ®Google Scholar
• Montagna D, Maccario R, Locatelli F, et al. Ex vivo priming for long term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood 2001; 98: 3359–66
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lening D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708–12
   PubMed Web of Science ®Google Scholar
• Sallusto F, Jenginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function generation and maintenance. Annu Rev Immunol 2004; 22: 745–63
   PubMed Web of Science ®Google Scholar
• Montagna D, Locatelli F, Moretta A, et al. T lymphocytes of recipient origin may contribute to the recovery of specific immune response towards viruses and fungi in children undergoing cord blood transplantation. Blood 2004; 103: 4322–9
   PubMed Web of Science ®Google Scholar
• Genginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation of human CD8+ memory T cell subsets in response to antigen or homeostatic cytokines. Blood 2003; 101: 4260–6
   PubMedGoogle Scholar
• Klebanoff CA, Gattinoni L, Torabi-Parizi, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector cells. PNAS 2005; 102: 9571–6
   PubMed Web of Science ®Google Scholar
• Wherry EG, Teichhgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4: 225–34
   PubMed Web of Science ®Google Scholar